Table 1.
Demographic and clinical characteristics
| DAT (n = 111) | bvFTD (n = 75) | Statistic | |
|---|---|---|---|
| Age years | 74.15 (7.53) | 64.46 (7.03) | t(184) = 8.84, P < 0.001 |
| Sex M/F | 68/43 | 51/24 | χ2(1) = 0.88, P = 0.348 |
| White/Black/Asian/multiple/unknown | 105/2/2/2/0 | 63/9/0/2/1 | Fisher’s exact = 10.80, P = 0.007 |
| Education years | 15.24 (3.31) | 16.05 (3.10) | t(184) = −1.67, P = 0.095 |
| CDR-SB | 5.38 (2.58) | 8.16 (3.94) | t(114.64) = −5.33, P < 0.001 |
| Days MRI—NPI-Q | 14.01 (55.81) | 4.03 (25.47) | t(165.04) = 2.96, P = 0.004 |
| Database ADNI/FTLDNI/Mesulam | 101/0/10 | 0/63/12 | |
| Disinhibition Yes/No | 27/84 | 62/13 | χ2(1) = 61.05, P < 0.001 |
| Disinhibition Severity 0/1/2/3 | 84/12/13/2 | 13/15/27/20 | χ2(3) = 67.49, P < 0.001 |
| Scanner Siemens/GE/Philips | 59/32/20 | 61/14/0 | χ2(1) = 20.89, P < 0.001 |
M, male; F, female; CDR-SB, Clinical Dementia Rating Scale Sum of Boxes; NPI-Q, Neuropsychiatric Inventory Questionnaire; ADNI, Alzheimer’s Disease Neuroimaging Initiative; FTLDNI, Frontotemporal Lobar Degeneration Neuroimaging Initiative; Mesulam, Mesulam Center for Cognitive Neurology and Alzheimer’s Disease; GE, General Electric.